Determinants and Trends of the Use of Intravenous Thrombolysis for Minor Stroke: A Population-Based Study, 2016 to 2020.


Journal

Stroke
ISSN: 1524-4628
Titre abrégé: Stroke
Pays: United States
ID NLM: 0235266

Informations de publication

Date de publication:
11 2022
Historique:
pubmed: 11 8 2022
medline: 27 10 2022
entrez: 10 8 2022
Statut: ppublish

Résumé

We analyzed the main factors associated with intravenous thrombolysis (IVT) in patients with minor ischemic stroke. Data were obtained from a prospective, government-mandated, population-based registry of stroke code patients in Catalonia (6 Comprehensive Stroke Centers, 8 Primary Stroke Centers, and 14 TeleStroke Centers). We selected patients diagnosed with ischemic stroke and National Institutes of Health Stroke Scale (NIHSS) ≤5 at hospital admission from January 2016 to December 2020. We excluded patients with a baseline modified Rankin Scale score of ≥3, absolute contraindication for IVT, unknown stroke onset, or admitted to hospital beyond 4.5 after stroke onset. The main outcome was treatment with IVT. We performed univariable and binary logistic regression analyses to identify the most important factors associated with IVT. We included 2975 code strokes; 1433 (48.2%) received IVT of which 30 (2.1%) had a symptomatic hemorrhagic transformation. Patients treated with IVT as compared to patients who did not receive IVT were more frequently women, had higher NIHSS, arrived earlier to hospital, were admitted to a Comprehensive Stroke Centers, and had large vessel occlusion. After binary logistic regression, NIHSS score 4 to 5 (odds ratio, 40.62 [95% CI, 31.73-57.22]; Minor stroke female patients, with higher NIHSS, arriving earlier to the hospital, presenting with large vessel occlusion and admitted to a Comprehensive Stroke Centers were more likely to receive intravenous thrombolysis.

Sections du résumé

BACKGROUND
We analyzed the main factors associated with intravenous thrombolysis (IVT) in patients with minor ischemic stroke.
METHODS
Data were obtained from a prospective, government-mandated, population-based registry of stroke code patients in Catalonia (6 Comprehensive Stroke Centers, 8 Primary Stroke Centers, and 14 TeleStroke Centers). We selected patients diagnosed with ischemic stroke and National Institutes of Health Stroke Scale (NIHSS) ≤5 at hospital admission from January 2016 to December 2020. We excluded patients with a baseline modified Rankin Scale score of ≥3, absolute contraindication for IVT, unknown stroke onset, or admitted to hospital beyond 4.5 after stroke onset. The main outcome was treatment with IVT. We performed univariable and binary logistic regression analyses to identify the most important factors associated with IVT.
RESULTS
We included 2975 code strokes; 1433 (48.2%) received IVT of which 30 (2.1%) had a symptomatic hemorrhagic transformation. Patients treated with IVT as compared to patients who did not receive IVT were more frequently women, had higher NIHSS, arrived earlier to hospital, were admitted to a Comprehensive Stroke Centers, and had large vessel occlusion. After binary logistic regression, NIHSS score 4 to 5 (odds ratio, 40.62 [95% CI, 31.73-57.22];
CONCLUSIONS
Minor stroke female patients, with higher NIHSS, arriving earlier to the hospital, presenting with large vessel occlusion and admitted to a Comprehensive Stroke Centers were more likely to receive intravenous thrombolysis.

Identifiants

pubmed: 35946402
doi: 10.1161/STROKEAHA.122.038996
doi:

Substances chimiques

Fibrinolytic Agents 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

3289-3294

Auteurs

Maria Àngels Font (MÀ)

Complex Hospitalari Moisès Broggi, Sant Joan Despí, Spain (M.A.F., S.M.G.-S., J.J.M., L.M., C.A., M.G.-C.).
Consorci Hospitalari de Vic, Spain (M.A.F., J.M.A.).
Escola de Doctorat, UVIC-UCC, Spain (M.A.F.).

Sonia María García-Sánchez (SM)

Complex Hospitalari Moisès Broggi, Sant Joan Despí, Spain (M.A.F., S.M.G.-S., J.J.M., L.M., C.A., M.G.-C.).

Juan José Mengual (JJ)

Complex Hospitalari Moisès Broggi, Sant Joan Despí, Spain (M.A.F., S.M.G.-S., J.J.M., L.M., C.A., M.G.-C.).

Luis Mena (L)

Complex Hospitalari Moisès Broggi, Sant Joan Despí, Spain (M.A.F., S.M.G.-S., J.J.M., L.M., C.A., M.G.-C.).

Carla Avellaneda (C)

Complex Hospitalari Moisès Broggi, Sant Joan Despí, Spain (M.A.F., S.M.G.-S., J.J.M., L.M., C.A., M.G.-C.).

Joaquín Serena (J)

Hospital Universitari Josep Trueta, Girona, Spain (J.S.).

Adrián Valls-Carbó (A)

Hospital Universitari Germans Trias i Pujol, Badalona, Spain (A.V.-C., N.P.d.l.O.).

Ángel Chamorro (Á)

Hospital Clínic of Barcelona, Spain (A.C.).

Xavier Ustrell (X)

Hospital Universitari Joan XXIII, Tarragona, Spain (X.U.).

Carlos Molina (C)

Hospital Universitari Vall d'Hebron, Barcelona, Spain (C.M.).

Pere Cardona (P)

Hospital Universitari de Bellvitge, L'Hospitalet de llobregat, Spain (P.C.).

Marina Guasch-Jiménez (M)

Hospital de la Santa Creu i Sant Pau, Barcelona, Spain (M.G.-J.).

Francisco Purroy (F)

Hospital Universitari Arnau de Vilanova, Lleida, Spain (F.P.).

Ana Rodríguez-Campello (A)

Hospital del Mar, Barcelona, Spain (A.R.-C.).

Ernest Palomeras (E)

Hospital de Mataró, Spain (E.P.).

Dolores Cocho (D)

Hospital de Granollers, Spain (D. Cocho).

Jerzy Krupinski (J)

Hospital Univeritari Mutua de Terrassa, Spain (J.K.).

David Cánovas (D)

Hospital Parc Taulí, Sabadell, Spain (D. Cánovas).

Jessica García-Alhama (J)

Hospital Comarcal de l'Alt Penedès, Vilafranca del Penedès, Spain (J.G.-A.).

José Zaragoza (J)

Hospital Verge de la Cinta, Tortosa, Spain (J.Z.).

Elsa Puiggròs (E)

Hospital Residència Sant Camil (E.P.).

Nuria Matos (N)

Hospital Altahia, Manresa, Spain (N.M.).

Josep Maria Aragonès (JM)

Consorci Hospitalari de Vic, Spain (M.A.F., J.M.A.).

Xavier Costa (X)

Hospital de Figueres, Spain (X.C.).

Eduard Sanjurjo (E)

Hospital Comarcal del Pallars, Tremp, Spain (E.S.).

Claudia Pedroza (C)

Fundació Sant Hospital, La Seu d'Urgell, Spain (C.P.).

Jordi Monedero (J)

Hospital d'Igualada, Spain (J.M.).

M Cruz Almendros (MC)

Hospital de Palamós, Spain (M.C.A.).

Maria Rybyeva (M)

Hospital d'Olot, Spain (M.R.).

Dolors Carrión (D)

Hospital de Mòra d'Ebre, Spain (D. Carrión).

Glòria Díaz (G)

Hopsital de Campdevànol, Spain (G.D.).

Miquel Barceló (M)

Hospital de la Cerdanya, Puigcerdá, Spain (M.B.).

Xavier Jiménez-Fàbrega (X)

Servei d'Emergencies Mèdiques (X.J.-F.).

Mercè Salvat-Plana (M)

Pla Director de la Malaltia Vascular Cerebral, Departament de Salut, Barcelona, Spain (M.S.-P., N.P.d.l.O.).
Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) (M.S.-P.).
CIBER en Epidemiología y Salud Pública (CIBERESP) (M.S.-P.).

Roberto Elosúa (R)

Universitat de Vic-Universitat Central de Catalunya, Barcelona, Spain (R.E.).
IMIM - Institut Hospital del Mar d'Investigacions Mèdiques, Barcelona, Spain (R.E.).
CIBER Cardiovascular Diseases, Instituto de Salud Carlos III, Madrid, Spain (R.E.).

Natalia Pérez de la Ossa (N)

Hospital Universitari Germans Trias i Pujol, Badalona, Spain (A.V.-C., N.P.d.l.O.).
Pla Director de la Malaltia Vascular Cerebral, Departament de Salut, Barcelona, Spain (M.S.-P., N.P.d.l.O.).

Manuel Gómez-Choco (M)

Complex Hospitalari Moisès Broggi, Sant Joan Despí, Spain (M.A.F., S.M.G.-S., J.J.M., L.M., C.A., M.G.-C.).

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH